Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Correlation of tumor burden in sentinel lymph nodes with tumor burden in non-sentinel lymph nodes and survival in cutaneous melanoma.

Namikawa K, Aung PP, Milton DR, Tetzlaff MT, Torres Cabala CA, Curry JL, Nagarajan P, Ivan D, Ross MI, Gershenwald JE, Prieto VG.

Clin Cancer Res. 2019 Sep 30. pii: clincanres.1194.2019. doi: 10.1158/1078-0432.CCR-19-1194. [Epub ahead of print]

PMID:
31570567
2.

Multiplex Immunofluorescence Assays.

Francisco-Cruz A, Parra ER, Tetzlaff MT, Wistuba II.

Methods Mol Biol. 2020;2055:467-495. doi: 10.1007/978-1-4939-9773-2_22.

PMID:
31502166
3.

Measurement of Tumor Thickness in Cutaneous Squamous Cell Carcinomas: Do the Different Methods Provide Better Prognostic Data?

Yildiz P, Aung PP, Milton DR, Hruska C, Ivan D, Nagarajan P, Tetzlaff MT, Curry JL, Torres-Cabala C, Prieto VG.

Am J Dermatopathol. 2019 Aug 22. doi: 10.1097/DAD.0000000000001511. [Epub ahead of print]

PMID:
31464719
4.

PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.

Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, Manyam GC, Korentzelos D, Park S, Tang Z, Wu C, Dong Z, Sigouros M, Sboner A, Beltran H, Chen Y, Corn PG, Tetzlaff MT, Troncoso P, Broom B, Thompson TC.

Clin Cancer Res. 2019 Aug 22. doi: 10.1158/1078-0432.CCR-19-0317. [Epub ahead of print]

PMID:
31439587
5.

A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.

Vashisht Gopal YN, Gammon S, Prasad R, Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S, Sudderth J, Sui D, Hudgens C, Fischer GM, Deng W, Reuben A, Peng W, Wang J, McQuade JL, Tetzlaff MT, Di Francesco ME, Marszalek J, Piwnica-Worms D, DeBerardinis RJ, Davies MA.

Clin Cancer Res. 2019 Aug 22. doi: 10.1158/1078-0432.CCR-19-0836. [Epub ahead of print]

PMID:
31439581
6.

Greater Tumor Thickness, Ulceration, and Positive Sentinel Lymph Node are Associated With Worse Prognosis in Patients With Conjunctival Melanoma: Implications For Future AJCC Classifications.

Esmaeli B, Rubin ML, Xu S, Goepfert RP, Curry JL, Prieto VG, Ning J, Tetzlaff MT.

Am J Surg Pathol. 2019 Aug 14. doi: 10.1097/PAS.0000000000001344. [Epub ahead of print]

PMID:
31425167
7.

Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features.

Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MT.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0340-7. [Epub ahead of print]

PMID:
31383963
8.

Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literature.

Mejbel HA, Nelson KC, Pradhan D, Ivan D, Zaleski M, Nagarajan P, Tetzlaff MT, Curry JL, Torres-Cabala CA, Prieto VG, Aung PP.

J Cutan Pathol. 2019 Jul 30. doi: 10.1111/cup.13551. [Epub ahead of print]

PMID:
31361351
9.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
10.

Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features.

Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, Yao JC, Nagarajan P, Aung PP, Torres-Cabala CA, Duvic M, Prieto VG, Huen A, Curry JL.

J Cutan Pathol. 2019 Jun 29. doi: 10.1111/cup.13536. [Epub ahead of print]

PMID:
31254410
11.

Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy.

Mauzo SH, Tetzlaff MT, Milton DR, Siroy AE, Nagarajan P, Torres-Cabala CA, Ivan D, Curry JL, Hudgens CW, Wargo JA, Sahin AA, Pettaway CA, Prieto VG, Aung PP.

Cancers (Basel). 2019 May 29;11(6). pii: E754. doi: 10.3390/cancers11060754.

12.

PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.

Nagarajan P, El-Hadad C, Gruschkus SK, Ning J, Hudgens CW, Sagiv O, Gross N, Tetzlaff MT, Esmaeli B.

Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2388-2398. doi: 10.1167/iovs.19-26894.

PMID:
31141610
13.

Prognostic Significance of "Nonsolid" Microscopic Metastasis in Merkel Cell Carcinoma Sentinel Lymph Nodes.

Erstine EM, Tetzlaff MT, Jia X, Aung PP, Prieto VG, Funchain P, Gastman BR, Billings SD, Ko JS.

Am J Surg Pathol. 2019 Jul;43(7):907-919. doi: 10.1097/PAS.0000000000001277.

PMID:
31094923
14.

Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.

Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA.

Cancer Immunol Res. 2019 Jun;7(6):1025-1035. doi: 10.1158/2326-6066.CIR-18-0619. Epub 2019 May 1.

PMID:
31043414
15.

IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy.

Johnson D, Patel AB, Uemura MI, Trinh VA, Jackson N, Zobniw CM, Tetzlaff MT, Hwu P, Curry JL, Diab A.

Cancer Immunol Res. 2019 Jun;7(6):860-865. doi: 10.1158/2326-6066.CIR-18-0682. Epub 2019 Apr 17.

PMID:
30996018
16.

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.

Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, Tetzlaff MT, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Aung S, Hwu P, Curti BD, Tannir NM, Sznol M, Diab A.

Cancer Discov. 2019 Jun;9(6):711-721. doi: 10.1158/2159-8290.CD-18-1495. Epub 2019 Apr 15.

PMID:
30988166
17.

Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response.

Curry JL, Reuben A, Szczepaniak-Sloane R, Ning J, Milton DR, Lee CH, Hudgens C, George S, Torres-Cabala C, Johnson D, Subramanya S, Wargo JA, Mudaliar K, Wistuba II, Prieto VG, Diab A, Tetzlaff MT.

J Cutan Pathol. 2019 Sep;46(9):627-636. doi: 10.1111/cup.13454. Epub 2019 Apr 11.

PMID:
30883858
18.

Validation Study of the AJCC Cancer Staging Manual, Eighth Edition, Staging System for Eyelid and Periocular Squamous Cell Carcinoma.

Xu S, Sagiv O, Rubin ML, Sa HS, Tetzlaff MT, Nagarajan P, Ning J, Esmaeli B.

JAMA Ophthalmol. 2019 May 1;137(5):537-542. doi: 10.1001/jamaophthalmol.2019.0238. Erratum in: JAMA Ophthalmol. 2019 May 1;137(5):587.

PMID:
30869769
19.

Predictors of Local Recurrence for Eyelid Sebaceous Carcinoma: Questionable Value of Routine Conjunctival Map Biopsies for Detection of Pagetoid Spread.

Sa HS, Tetzlaff MT, Esmaeli B.

Ophthalmic Plast Reconstr Surg. 2019 Sep/Oct;35(5):419-425. doi: 10.1097/IOP.0000000000001343.

PMID:
30865067
20.

Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

Ferguson SD, Bindal S, Bassett RL Jr, Haydu LE, McCutcheon IE, Heimberger AB, Li J, O'Brien BJ, Guha-Thakurta N, Tetzlaff MT, Tawbi H, Davies MA, Glitza IC.

J Neurooncol. 2019 May;142(3):499-509. doi: 10.1007/s11060-019-03121-2. Epub 2019 Mar 7.

PMID:
30847840
21.

B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density.

Aung PP, Parra ER, Barua S, Sui D, Ning J, Mino B, Ledesma DA, Curry JL, Nagarajan P, Torres-Cabala CA, Efstathiou E, Hoang AG, Wong MK, Wargo JA, Lazar AJ, Rao A, Prieto VG, Wistuba I, Tetzlaff MT.

Clin Cancer Res. 2019 Jun 1;25(11):3455-3467. doi: 10.1158/1078-0432.CCR-18-2355. Epub 2019 Feb 26.

PMID:
30808776
22.

Melanoma With Loss of BAP1 Expression in Patients With No Family History of BAP1-Associated Cancer Susceptibility Syndrome: A Case Series.

Aung PP, Nagarajan P, Tetzlaff MT, Curry JL, Tang G, Abdullaev Z, Pack SD, Ivan D, Prieto VG, Torres-Cabala CA.

Am J Dermatopathol. 2019 Mar;41(3):167-179. doi: 10.1097/DAD.0000000000001217.

PMID:
30801340
23.

Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.

Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA.

Cancer Discov. 2019 May;9(5):628-645. doi: 10.1158/2159-8290.CD-18-1489. Epub 2019 Feb 20.

PMID:
30787016
24.

Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.

Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR.

Nat Med. 2019 Jan;25(1):188. doi: 10.1038/s41591-018-0305-2.

PMID:
30479380
25.

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.

Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR.

Nat Med. 2018 Dec;24(12):1804-1808. doi: 10.1038/s41591-018-0238-9. Epub 2018 Nov 12. Erratum in: Nat Med. 2018 Nov 27;:.

PMID:
30420754
26.

Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations.

Tetzlaff MT, Curry JL, Ning J, Sagiv O, Kandl TL, Peng B, Bell D, Routbort M, Hudgens CW, Ivan D, Kim TB, Chen K, Eterovic AK, Shaw K, Prieto VG, Yemelyanova A, Esmaeli B.

Clin Cancer Res. 2019 Feb 15;25(4):1280-1290. doi: 10.1158/1078-0432.CCR-18-1688. Epub 2018 Nov 12.

PMID:
30420449
27.

Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread.

Fedda F, Migden MR, Curry JL, Torres-Cabala CA, Tetzlaff MT, Aung PP, Prieto VG, Ivan D, Myers JN, Nagarajan P.

J Cutan Pathol. 2019 Feb;46(2):152-158. doi: 10.1111/cup.13388. Epub 2018 Dec 11.

PMID:
30414196
28.

Pathological Features and Clinical Course in Patients With Recurrent or Malignant Orbital Solitary Fibrous Tumor/Hemangiopericytoma.

Sagiv O, Bell D, Guo Y, Su S, Wester ST, Jiang K, Yin VT, Shinder R, Hayek B, Kim HJ, Tetzlaff MT, Esmaeli B.

Ophthalmic Plast Reconstr Surg. 2019 Mar/Apr;35(2):148-154. doi: 10.1097/IOP.0000000000001189.

PMID:
30371551
29.

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1942. doi: 10.1038/s41591-018-0252-y.

PMID:
30361511
30.

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0251-z.

PMID:
30361510
31.

Melanoma coexisting with solar elastosis: a potential pitfall in the differential diagnosis between nevus and melanoma.

Konopinski JC, Danialan R, Torres-Cabala CA, Tetzlaff MT, Nagarajan P, Curry JL, Ivan D, Prieto VG, Aung PP.

Hum Pathol. 2019 Feb;84:270-274. doi: 10.1016/j.humpath.2018.10.010. Epub 2018 Oct 22.

PMID:
30359637
32.

DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway.

Adam L, San Lucas FA, Fowler R, Yu Y, Wu W, Liu Y, Wang H, Menter D, Tetzlaff MT, Ensor J Jr, Manyam G, Arold ST, Huff C, Kopetz S, Scheet P, Overman MJ.

Clin Cancer Res. 2019 Jan 15;25(2):641-651. doi: 10.1158/1078-0432.CCR-18-1480. Epub 2018 Oct 23.

PMID:
30352910
33.

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Nov;24(11):1649-1654. doi: 10.1038/s41591-018-0197-1. Epub 2018 Oct 8. Erratum in: Nat Med. 2018 Oct 25;:. Nat Med. 2018 Oct 25;:.

34.

Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes.

Crumley S, Kurnit K, Hudgens C, Fellman B, Tetzlaff MT, Broaddus R.

Mod Pathol. 2019 Mar;32(3):396-404. doi: 10.1038/s41379-018-0148-x. Epub 2018 Oct 5.

35.

Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility.

Kaur A, Ecker BL, Douglass SM, Kugel CH 3rd, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, Franco-Barraza J, Shah N, Mellis IA, Keeney F, Kossenkov A, Tang HY, Yin X, Liu Q, Xu X, Fane M, Brafford P, Herlyn M, Speicher DW, Wargo JA, Tetzlaff MT, Haydu LE, Raj A, Shenoy V, Cukierman E, Weeraratna AT.

Cancer Discov. 2019 Jan;9(1):64-81. doi: 10.1158/2159-8290.CD-18-0193. Epub 2018 Oct 2.

PMID:
30279173
36.

Post-radiation vascular lesions of the breast.

Ronen S, Ivan D, Torres-Cabala CA, Curry JL, Tetzlaff MT, Aung PP, Nagarajan P, Suster S, Prieto VG.

J Cutan Pathol. 2019 Jan;46(1):52-58. doi: 10.1111/cup.13363. Epub 2018 Nov 4. Review.

PMID:
30251277
37.

High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma.

Kandl TJ, Sagiv O, Curry JL, Ning J, Ma J, Hudgens CW, Van Arnam J, Wargo JA, Esmaeli B, Tetzlaff MT.

Oncoimmunology. 2018 Jul 26;7(9):e1475874. doi: 10.1080/2162402X.2018.1475874. eCollection 2018.

38.

Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients.

Lefrançois P, Xie P, Wang L, Tetzlaff MT, Moreau L, Watters AK, Netchiporouk E, Provost N, Gilbert M, Ni X, Sasseville D, Wheeler DA, Duvic M, Litvinov IV.

Oncoimmunology. 2018 May 31;7(8):e1467856. doi: 10.1080/2162402X.2018.1467856. eCollection 2018.

39.

Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs.

Vishnoi M, Boral D, Liu H, Sprouse ML, Yin W, Goswami-Sewell D, Tetzlaff MT, Davies MA, Oliva ICG, Marchetti D.

Cancer Res. 2018 Sep 15;78(18):5349-5362. doi: 10.1158/0008-5472.CAN-18-0644. Epub 2018 Jul 19.

40.

Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor.

Arudra K, Patel R, Tetzlaff MT, Hymes S, Subbiah V, Meric-Bernstam F, Torres-Cabala C, Aung PP, Nagarajan P, Diab A, Prieto VG, Nelson K, Curry JL.

J Cutan Pathol. 2018 Oct;45(10):786-790. doi: 10.1111/cup.13319. Epub 2018 Aug 3.

PMID:
30021048
41.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA.

Ann Oncol. 2018 Aug 1;29(8):1861-1868. doi: 10.1093/annonc/mdy226.

42.

Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.

Chen WS, Tetzlaff MT, Diwan H, Jahan-Tigh R, Diab A, Nelson K, Glitza IC, Kaunitz GJ, Johnson D, Torres-Cabala C, Pacha O, Taube JM, Maloney K, Prieto VG, Curry JL.

J Cutan Pathol. 2018 Oct;45(10):764-773. doi: 10.1111/cup.13312. Epub 2018 Jul 24.

PMID:
29943453
43.

Spitzoid melanoma with histopathological features of ALK gene rearrangement exhibiting ALK copy number gain: a novel mechanism of ALK activation in spitzoid neoplasia.

Farah M, Nagarajan P, Curry JL, Tang Z, Kim TB, Aung PP, Torres-Cabala CA, Eterovic AK, Wargo JA, Prieto VG, Tetzlaff MT.

Br J Dermatol. 2019 Feb;180(2):404-408. doi: 10.1111/bjd.16881. Epub 2018 Sep 12.

PMID:
29897634
44.

Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall.

Curry JL, Tetzlaff MT, Wang SA, Landon G, Alouch N, Patel SP, Nagarajan P, Gupta S, Aung PP, Devine CE, Khoury JD, Loghavi S, Prieto VG, DiNardo CD, Gershenwald JE.

Am J Dermatopathol. 2018 Nov;40(11):831-835. doi: 10.1097/DAD.0000000000001150.

PMID:
29863571
45.

Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall.

Farah M, Nagarajan P, Torres-Cabala CA, Curry JL, Amaria RN, Wargo J, Tawbi H, Ivan D, Prieto VG, Tetzlaff MT, Aung PP.

J Cutan Pathol. 2018 Jul;45(7):545-549. doi: 10.1111/cup.13263. Epub 2018 May 18.

PMID:
29672900
46.

Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features.

Dolkar T, Trinidad CM, Nelson KC, Amaria RN, Nagarajan P, Torres-Cabala CA, Ivan D, Prieto VG, Tetzlaff MT, Curry JL, Aung PP.

J Cutan Pathol. 2018 Jul;45(7):539-544. doi: 10.1111/cup.13262. Epub 2018 May 16.

PMID:
29665030
47.

Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers.

Mauzo SH, Milton DR, Prieto VG, Torres-Cabala CA, Wang WL, Chakravarti N, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Brown RE, Aung PP.

Ann Diagn Pathol. 2018 Jun;34:151-154. doi: 10.1016/j.anndiagpath.2018.03.005. Epub 2018 Mar 15.

PMID:
29660567
48.

Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.

Trinidad C, Nelson KC, Glitza Oliva IC, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Ivan D, Hwu WJ, Prieto VG, Curry JL, Aung PP.

J Cutan Pathol. 2018 Jul;45(7):504-507. doi: 10.1111/cup.13150. Epub 2018 Apr 23.

PMID:
29633300
49.

Intratumoral and peritumoral lymphovascular invasion detected by D2-40 immunohistochemistry correlates with metastasis in primary cutaneous Merkel cell carcinoma.

Al-Rohil RN, Milton DR, Nagarajan P, Curry JL, Feldmeyer L, Torres-Cabala CA, Ivan D, Prieto VG, Tetzlaff MT, Aung PP.

Hum Pathol. 2018 Jul;77:98-107. doi: 10.1016/j.humpath.2018.03.017. Epub 2018 Mar 28.

PMID:
29601841
50.

Update on Merkel Cell Carcinoma.

Tetzlaff MT, Nagarajan P.

Head Neck Pathol. 2018 Mar;12(1):31-43. doi: 10.1007/s12105-018-0898-2. Epub 2018 Mar 20. Review.

Supplemental Content

Loading ...
Support Center